Expression of inducible nitric oxide synthase (iNOS) is generally accompanied by a parallel upregulation in L-arginine transport which is dependent, at least in part, on the synthesis of new carrier proteins. It is not clear however whether the induction of iNOS and its subsequent utilisation of L-arginine for NO synthesis contribute to the enhancement in L-arginine transport rates observed following induction of cells with pro-inXammatory mediators. To address this issue, we have transfected an iNOS construct in a pEGFP-N1 vector into HEK-293 cells and investigated the eVects this has on L-arginine transport. The expression of iNOS through transfection resulted in the production of signiWcant quantities of NO as detected by the standard Griess assay. Under these conditions, the transport of L-arginine was found to be unaltered, with rate of uptake being comparable in both transfected and non-transfected cells. Characterisation of the transporter(s) involved with uptake of L-arginine revealed features characteristic of the classical cationic amino acid transport system y + . Further analysis of the expression proWle of the cationic amino acid transporter (CAT) involved revealed the presence of transcripts for CAT-1 and CAT-2B. These data demonstrate that iNOS activity does not drive or enhance L-arginine transport despite the fact that HEK-293 cells transport L-arginine via the CATs, including CAT-2B which is thought to be critical for supply of substrate to iNOS.  2004 Published by Elsevier Inc.
Expression of inducible nitric oxide synthase (iNOS) in various cells and tissues is associated with the overproduction of nitric oxide (NO) which although critical for immune defences also functions as an important mediator of inXammatory responses with detrimental consequences. For instance, iNOS produced NO is believed to be responsible for the systemic hypotension seen in septic shock [1] [2] [3] and has been implicated in the pathogenesis of several other inXammatory diseases, including asthma [4] and inXammatory bowel disease [5] . Once expressed, synthesis of NO by iNOS is critically dependent on the availability and transport of L-arginine [6] [7] [8] [9] [10] . The induction of iNOS by pro-inXammatory mediators is accompanied by a parallel upregulation in L-arginine transport [7, [11] [12] [13] which is due at least in part to enhanced expression of transcripts for cationic amino acid transporters (CATs), including CAT-1, 2B, and potentially 2A [14, 15] . This parallel upregulation in CAT expression and activity provides a mechanism for sustaining substrate supply during enhanced synthesis of NO by iNOS. It is not known, however, whether the expression of iNOS and the subsequent enhanced utilisa-2
Z. Cui et al. / Nitric Oxide xxx (2004) xxx-xxx
tion of L-arginine by this enzyme directly regulate CAT expression and function. One report in the literature has indicated that inhibition of iNOS activity using either 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine (AMT), a potent and selective inhibitor of iNOS [16] or S-ethylisothiourea, a potent but non-selective NOS inhibitor [17] , abolished LPS-induced L-arginine transport [18] .
The same group has also demonstrated that expression of both iNOS and CAT-2B mRNA may be downregulated after prolonged (20 h) exposure of rat alveolar macrophages to dexamethasone. These eVects were accompanied by corresponding decreases in both LPSstimulated nitrite production and L-[ 3 H]arginine transport, suggesting a parallel regulation of the expression and function of iNOS and CAT-2B, at least in rat alveolar macrophages [19] . These Wnding are, however, at odds with previous studies in the murine macrophage J774 cell line [20] and in rat cultured aortic smooth muscle cells [13, 21] in which dexamethasone selectively blocked iNOS expression whilst having no eVect on induced L-arginine transport, suggesting that upregulation of transport may be independent of iNOS activity. These studies did not however take into account the fact that other pathways which utilise L-arginine may also be switched on in activated cells, thus masking any direct coupling between utilisation of L-arginine by iNOS and the subsequent regulation of transport that may occur as a consequence of the activity of this enzyme.
To determine unequivocally whether CAT function is inXuenced by the activity of iNOS we therefore deliberately chose to use an experimental system in which iNOS could be expressed and was fully active in cells in the absence of pro-inXammatory stimuli. Transient iNOS expression was therefore induced by transfection in human embryonic kidney-293 (HEK-293 cells). These cells can be easily transfected but do not express endogenous iNOS or show any upregulation in CAT activity following exposure to the standard cocktail of bacterial lipopolysaccharide (LPS) and cytokines generally used to induce these pathways in other cells (unpublished observations). In parallel studies, the characteristics of Larginine transport have been fully investigated and the nature of the transporters involved with L-arginine uptake established. These studies are essential since very little is currently known about the mechanism of entry of L-arginine into HEK293 cells. Moreover, the transporters expressed may potentially determine the manner in which NO synthesis is regulated in these cells.
Experimental procedure

Materials
Tissue culture reagents were obtained from Invitrogen (Paisley, UK 
Cell culture
HEK-293 cells were maintained in Dulbecco's modiWed Eagle's medium (DMEM) supplemented with penicillin (100 U ml ¡1 ), streptomycin (100 g ml ¡1 ), and 10% foetal bovine serum. Cells were harvested by trypsinisation and passaged every 5 days by dilution of a suspension of the cells 1:4 in fresh medium.
RNA isolation
Total cellular RNA was isolated from the cultured cells using RNA STAT-60 (Biogenesis, Poole, UK) according to the manufacturer's protocol. The concentration of RNA solutions was determined spectrophotometrically and the quality veriWed by visualisation of 28S and 18S rRNA bands after electrophoresis through a 1% ethidium bromide stained agarose gel.
Construction of iNOS-pEGFP-N1 Plasmid
Total RNA was extracted from rat (Wistar) cultured aortic smooth muscle cells activated with bacterial lipopolysaccharide (LPS; 100 g ml ¡1 ) and interferon-(IFN-; 50 U ml ¡1 ) for 24 h. The Wrst strand cDNA was synthesised from 1 g total RNA using the Clontech SMART system (BD Biosciences Clontech, Cowley, UK) and an iNOS gene-speciWc reverse primer (5Ј-GAG TCT TGT GCC TTT GGG CT-3Ј) based on a published rat iNOS cDNA sequence (Accession No.: X76881). The cDNA products were subsequently ampliWed by PCR using the SMART RACE cDNA AmpliWcation Kit together with the above reverse primer, lacking the nucleotide sequence for the iNOS stop codon. To facilitate translation initiation and enhance iNOS-GFP expression levels, a modiWed iNOS forward primer was designed with a Kozak consensus sequence introduced around the initiation codon of iNOS (5Ј-CAC CGC CAT GGC TTG CCC CTG GAA-3Ј). A 3.449 kb cDNA fragment ampliWed was ligated into pcDNA3.1 using the Eukaryotic TOPO TA Cloning Kit. After transformation into E. coli, a mini-preparation of the plasmid was made and the puriWed cDNA sequenced using a Beckman Coulter CEQ2000XL Sequencer. The iNOS-GFP expression vector was subsequently constructed by digesting pcDNA 3.1 harbouring the iNOS cDNA with HindIII and SacII, and then subcloning the restricted iNOS cDNA from pcDNA3.1 into the HindIII and SacII sites of the pEGFP-N1 vector. The iNOS sequence was fused at its C terminal to GFP and was driven directly by the CMV promoter of the plasmid.
Transfection of HEK293 cells with iNOS-pEGFP-N1
ConXuent monolayers of HEK-293 cells in T75 tissue culture Xasks were trypsinised and plated into 24-well plates at a seeding density of 2 £ 10 4 cells per well. Cells were allowed to grow to 60% conXuency prior to transfecting with iNOS-pEGFP-N1 using an 5 1 integrinbinding polycationic peptide ([K] 16 GACRRETAWA CG; Peptide 6) [22] . For optimum transfection eYciency, conditions previously described [22] were adhered to. BrieXy, culture medium was removed from wells and the adherent cells washed twice with PBS. 0.5 ml of transfection complex in Opti-MEM I medium containing lipofectin (0.75 l), plasmid (1 g), and peptide 6 (4 g) was then added to each well. Cells were incubated for a further 3 h at 37°C, after which the medium was removed, replace with normal culture medium containing 10% FCS and incubated in a tissue culture incubator at 37°C for 6-48 h before determining accumulated nitrite levels in the culture medium as described below. In parallel experiments cells were also incubated with the potent and highly selective iNOS inhibitor GW274150 (S-[2-[(1-iminoethyl)amino]ethyl]-L-homocysteine) to inhibit NO production [23] . In control experiments cells were transfected with either empty vector or pEGF-N1 vector alone. Transfected cells were routinely visualised using a Nikon EFD 3 Labophot-2 Xuorescence microscope and the transfection eYciency determined from the proportion of green Xuorescing cells. The estimated transfection eYciency generally obtained with the above protocol was between 60 and 70%. Batches of cells showing <50% transfection were discarded. There was no detectable Xuorescence in cells transfected with the empty non-GFP vector alone.
Western blot analysis of iNOS expression
Western blotting was carried out as described previously [24] . Cell lysates (20 g protein per lane) were separated by SDS-PAGE electrophoresis, transferred onto PVDF membrane (Sigma-Aldrich, Poole, UK) and blocked for 2 h in 100 mM NaCl, 10 mM Tris, 0.1% (v/v) Tween 20, pH 7.4 (STT), containing 5% (w/v) non-fat milk. Membranes were then incubated overnight with either a monoclonal anti-iNOS (1:2500 dilution) or anti-GFP (1:1000 dilution) antibody in STT containing 5% (w/v) non-fat milk). Blots were washed with STT (6 £ 5 min) and incubated with a 1:10,000 dilution of horseradish peroxidase-conjugated goat anti-mouse antibody for 1 h. Following further washing (6 £ 5 min) in STT, immunoreactive bands were visualised using ECL detection System (Amersham-Pharmacia, Buckinghamshire, UK).
Measurement of nitrite formation
Measurement of nitrite production as an assay of NO release was carried out as described previously [24] using the Griess reaction with sodium nitrite as standard [25] .
Measurement of L-arginine transport
Unidirectional transport of L-arginine was measured in cell monolayers as described previously [20] . Cells were rinsed twice with a modiWed Hepes-buVered Krebs solution (composition (mM): NaCl, 131; KCl, 5. ) to each well and inXux measured over 1 min. The eVects of pH on transport were examined in Krebs solution with pH values ranging between pH 6 and 7.4. In parallel experiments, the sodium-dependency of transport was examined in modiWed buVer in which NaCl, NaHCO 3 , and NaH 2 PO 4 were replaced with choline chloride, choline bicarbonate, and KH 2 PO 4 , respectively. Uptake of L- [ 3 H]arginine was terminated by placing plates on ice and rinsing cells twice with 200 l ice-cold Krebs containing 10 mM unlabelled L-arginine. Cell protein was determined using bicinchoninic acid (BCA) protein assay reagent following the manufacturer's protocol. Radioactivity (dpm) in cell lysates was measured by liquid scintillation counting. Transport was expressed in pmol g protein ¡1 min ¡1 .
ProWle of CAT expression in HEK-293 cells
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Statistics
All values are means § SE of measurements in at least three diVerent cell cultures with two replicates per experiment. ANOVA was used to determine statistical signiWcance between paired values with the overall conWdence levels set at 95% (0.05).
Results
Cloning, sequence, and analysis of iNOS cDNA
A 3.449 kb cDNA fragment was ampliWed by PCR as described in methods using iNOS gene speciWc primers and the sequence obtained submitted to GenBank (Accession No.: AY211532). The cDNA produced encodes the full-length iNOS protein when inserted into the multiple cloning site of the pEGP-N1 plasmid and driven by the CMV promoter of the plasmid. The Wrst six bases at the 5Ј end of the cDNA produced were not part of the iNOS sequence. Instead, these six bases constituted the Kozak consensus translation initiation site for iNOS. The remaining sequence represents that for iNOS. Sequence comparison revealed our cloned iNOS cDNA to be highly homologous (>99.5%) with two other published rat iNOS sequences, showing 17 singlebase mismatches to that published by Nunokawa et al. [26, Accession No. : D14051], and 13 single-base mismatches to the sequence published by Geng et al. [27, Accession No.: X76881] . These small diVerences occur as sporadically placed amino acid substitutions ( Fig. 1) with no insertion or deletion mutations being apparent between the clones. Our cDNA also shows a high level of homology at the cDNA level to the inducible enzyme from human [28] and mouse [29] . It contains a single open reading frame beginning with an AUG methionine at codon 1 and encodes a protein of 1147 residues with a calculated molecular mass of 130.67 kDa. It also contains the predicted consensus recognition sites for the various cofactors including FMN (at amino acids: 620-639), FAD-PPi (at amino acids: 764-777), FAD-ISO (at amino acids: 900-910), NADPH-Ribose (at amino acids: 973-992), and NADPH-Ade (at amino acids: 1074-1088) in the C-terminal and for calmoduline (at amino acids 502-527) in the mid portion. Following sequencing and analysis, the fragment produced was subsequently subcloned into the HindIII and SacII sites of the pEGFP-N1 vector and used in expression studies.
EYciency of transfection of iNOS using peptide 6
Transfection of HEK-293 cells with iNOS-pEGFP-N1 using peptide 6 under optimised conditions reported previously [22] resulted in detectable expression of GFP in 60-70% of cells. As shown in Fig. 2 , visualisation of transfected cells by Xuorescence microscopy conWrms signiWcant expression of GFP at 6 h ( Fig. 2A) with levels increasing over time, reaching a peak at 24-48 h (Fig.  2D ) but declining by 72 h due to marked decreases in cell viability (data not shown).
Western blot analysis of lysates carried out in parallel reXects a time-dependent expression of GFP which as shown in Fig. 3A , was detectable after 6 h, peaking at 24 h. Expression of iNOS was evident after 6 h and was maximal at 12 h remaining at this level over the 48 h incubation period (Fig. 3B) . 275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303 
EVects of iNOS expression on nitrite production
Transfection of cells with iNOS-pEGFP-N1, but not with empty or pEGFP-N1 vector, resulted in the expression of iNOS (Fig. 3B ) and a marked increase in NO production which was reXected in a time-dependent increase in accumulated nitrite levels in the culture medium (Fig. 4A) . Moreover the maximum amount of NO produced (56 § 0.03 pmol g protein ¡1 nitrite at 48 h) was well within the range detected following induction of iNOS in various cells systems using inXammatory mediators such as bacterial lipopolysaccharide and/or cytokines. To conWrm that the detected nitrite is generated by iNOS, additional experiments were carried out in which transfected cells were co-incubated with the highly selective iNOS inhibitor GW274150. As shown in Fig. 5A , accumulated nitrite production was abolished by 10 M GW274150, conWrming iNOS as the source of the NO produced.
EVects of iNOS expression on L-arginine transport
HEK-293 cells transported L-[
3 H]arginine in a timedependent manner which was linear over 5 min in both transfected and non-transfected cells (data not shown). As a result all subsequent uptake studies were carried out over 1 min. The rate of uptake in 48 h controls was 1.91 § 0.03 pmol g protein ¡1 min ¡1 and there was no signiWcant change in transporter activity in NO-generating transfected cells expressing iNOS (Fig. 4B) . Inhibition of NO synthesis with GW274150 did not cause any signiWcant change in transport (Fig. 5B) . Transfection of cells with empty (data not shown) or pEGFP-N1 vector alone did not alter L-arginine transport (Fig. 4B) .
ProWle of CAT expression and activity in HEK-293 cells
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In kinetic studies, entry of L-arginine was monitored over the concentration range 5-1000 M. Transport was found to be saturable (Fig. 7) with a K m of 0.21 mM and V max of 5.3 nmol g protein ¡1 min ¡1 and occurred via a single carrier system as evident from the Eadie-Hofstee plot in Fig. 7 (inset) .
In competition experiments the substrate speciWcity of L-arginine transport was examined by screening the inhibitory eVects of a series of 1 mM unlabelled amino acids on uptake of 0.1 mM L- [ 3 H]arginine. As shown in Table 1 , transport of L-arginine was unaVected by selective substrates for system A (preferred substrate: 2-methylaminoisobutyric acid (MeAIB; [30] ), ACS (preferred substrate: L-serine, L-alanine [31] ), L (preferred substrate: 2-aminobicyclo-(2,2,1)heptane-2-carboxylic acid (BCH, [32] ), and N (preferred substrate: 6-diazo-5-oxo-L-norleucine (DON, [33] ) but signiWcantly inhibited by other cationic amino acids, L-lysine and L-ornithine (Table 1 ). In addition, transport was found to be unaVected by changes in extracellular Na + or pH ranging from 6 to 7.4 (Table 2). 499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554   555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609 
Discussion
Production of NO by iNOS in several cell systems depends critically on the availability and transport of Larginine. More importantly, the expression of iNOS under these conditions is accompanied by a parallel upregulation in L-arginine transporter activity. This widely reported phenomenon [7, 12, 13, [34] [35] [36] provides a mechanism for sustaining substrate supply during enhanced synthesis of NO, and is thus a key target for regulating NO synthesis by iNOS. Previous work has, however, not determined whether the increase in transporter activity is a direct consequence of increased iNOS activity resulting in enhanced substrate uptake into the cells.
To resolve this question we have examined whether transiently expressing iNOS in non-induced cells can regulate the rate of L-arginine transport as a consequence of the increased utilisation of the amino acid for NO synthesis. These studies were carried out in HEK-293 cells transfected with an iNOS construct in pEGFP-N1 vector using a synthetic peptide comprising of an integrin-targeting ( 5 1 integrin selective) arginine-glycine-aspartic acid tripeptide motif and a DNA-binding moiety of 16 lysine residues [22] . This novel transfection strategy resulted in consistently high transfection eYciency where 750% of cells appeared transfected. More importantly, the levels of iNOS protein expressed and the amounts of NO produced were comparable to those detected in various cell systems following induction with pro-inXammatory mediators [7, 10, 13, 35, 36] . This Wnding validates the use of peptide 6 as an eVective nonviral system for iNOS gene transfer in HEK-293 cells.
However, despite the prominent expression of iNOS and marked production of NO achieved, parallel transport studies failed to show any modiWcation of L-arginine transport: the transport rate in transfected cells was not signiWcantly diVerent when compared to rates determined in control non-transfected cells. This observation demonstrates that the expression of iNOS alone is not suYcient to upregulate L-arginine uptake into cells. In this regard, we and others have demonstrated that increases in L-arginine transport are sensitive to inhibition by cycloheximide and associated with a marked increase in the expression of transcripts for CATs, indicating a critical requirement for protein synthesis of the L-arginine transporter itself [7, 14, 15, 20, 21] . 
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Our results therefore provide the Wrst direct evidence that expression of active iNOS is by itself insuYcient to upregulate CAT function and hence arginine transport. This conclusion is apparently in conXict with a recent report by Hammermann et al. [18] , which suggests that direct inhibition of iNOS activity in rat alveolar macrophages is suYcient to abolish LPS-activated L-arginine uptake. The inhibitor of iNOS primarily used in those experiments (AMT) did not inhibit basal arginine inXux in control cells but inhibited enhanced arginine uptake in LPS-pretreated cells even with brief pre-incubations. The authors therefore concluded that this was an indirect eVect due to reduced arginine utilisation by iNOS. This association is however questionable since L-arginine transport: (i) occurs by facilitated diVusion driven by the membrane potential, (ii) accumulates L-arginine against a concentration gradient, and (iii) is sensitive to transstimulation when substrate concentrations are high on the opposite side of the cell membrane [37, 38] . Thus, if inhibition of L-arginine utilisation by iNOS results in elevated intracellular levels of this amino acid, entry of radiolabelled L-arginine would be enhanced via transstimulation causing an increase in L- [ 3 H]arginine uptake. As we observed no signiWcant changes in accumulated L-[ 3 H]arginine in cells transfected with our iNOS construct, we conclude that activation of iNOS itself does not inXuence rates of L-arginine transport. It could be argued that in the system used by Hammermann et al. [18] , activation of cells may result in the co-induction of linker proteins which may facilitate compartmentalised regulation of L-arginine transport and NO synthesis. This, however, still remains to be established and the coupling of L-arginine transport to NO synthesis may not be a widespread phenomenon in all activated cell types [13, 20, 21] .
DiVerences in the proWle of expression of L-arginine transporter systems may explain the discrepancy between our study and those of Hammermann et al. [18] . This latter point is important since there are suggestions in the literature that CATs may be linked to diVerent NOS enzymes, thereby providing a direct supply of substrate for that isoform. In this regard, CAT-1 is thought to supply substrate to endothelial NOS by virtue of its co-localisation with this enzyme [39] . CAT-2B on the other hand may regulate supply of L-arginine to iNOS as these proteins are co-induced in cells where neither is constitutively expressed. Moreover, in such systems, the induction of CAT-2B can be accompanied by a parallel downregulation in CAT-1 mRNA [14] , thereby making CAT-2B the critical transporter in these cells.
Since the nature of the transporters associated with Larginine uptake had not previously been characterised in HEK-293 cells, we have therefore examined the characteristics of L-arginine transport and the proWle of expression of CATs in these cells. Kinetic studies and EadieHofstee analysis show that entry of L-arginine occurs predominantly via a single saturable carrier that is of relatively low capacity but of high aYnity for L-arginine. Transport was selectively inhibited by the cationic amino acids L-lysine, L-ornithine, and by L-arginine itself. Substrates for amino acid transport systems A/ASC, N, and L were without signiWcant eVect. This inhibition proWle together with the Na + and pH insensitivity strongly implicate the CATs as the predominant carrier of L-arginine in HEK-293 cells and excludes other systems such as y + L, b o,+ , and B o,+ which are broad scope in nature, transporting both cationic and neutral amino acids [38, 40] .
To identify the CAT or CATs expressed in HEK-293 cells we carried out RT-PCR of total RNA isolated from these cells using CAT-1, CAT-2A, and CAT-2B-speciWc primers respectively. CAT-3 was not investigated since this transporter is thought to be expressed predominantly in brain [41, 42] and thymus tissue [43] and also interacts with neutral amino acids [41] . The data obtained show that HEK-293 cells express transcripts for CAT-1 and CAT-2B but not for CAT-2A. This expression proWle agrees with the functional studies in that the kinetics of uptake reXects a high aYnity system or systems with indistinguishable characteristics at the functional level. Although, CAT-2A and CAT-2B are spliced variants with high percentage structural homology they are functionally distinguishable by virtue of the fact that CAT-2A is a high capacity but low aYnity carrier while CAT-2B exhibits similar functional characteristics to those of CAT-1 [44] [45] [46] . Both these carriers have a high aYnity for L-arginine, transporting the latter with a Michaelis constant (K m ) of between 0.14 and 0.38 mM. The K m of 0.21 mM determined in our study therefore supports CAT-1 and CAT-2B as being the predominant carriers of L-arginine into HEK-293 cells.
At present we cannot distinguish between CAT-1 and CAT-2B in terms of their relative contribution to total Larginine uptake nor can we specify which CAT directly supplies L-arginine to transfected iNOS in our cell system. However, the detection of CAT-2B transcripts, generally believed to be expressed under inXammatory conditions in parallel with iNOS, suggests that this protein can exist endogenously in control conditions and may not require induction. More importantly, its detection excludes the possibility that iNOS was not able to alter transport in our studies because of lack of expression of the critical CAT (CAT-2B) associated with uptake of L-arginine for utilisation by this enzyme.
In conclusion, our current Wndings provide the Wrst direct evidence that CATs function independently of iNOS and that the rate of transport of L-arginine into cells is not modulated by the activity of iNOS. Thus, the enhancement in L-arginine transport observed in systems where expression of iNOS and the subsequent generation of large quantities of NO are induced must occur via mechanisms not directly related to the rate of con- sumption of L-arginine or generation of NO by iNOS. These mechanisms presumably involve activation by external stimuli of common upstream signalling pathways leading to upregulation of iNOS and CAT expression [15] . 835  836  837  838  839   840   841  842   843   844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891 
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